Genetically Elevated Apolipoprotein A-I, High-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
CONTEXT: Epidemiologically, levels of high-density lipoprotein (HDL) cholesterol and its major protein constituent, apolipoprotein A-I (apoA-I), are inversely related to risk of ischemic heart disease (IHD). OBJECTIVE: We tested whether common genetic variation in the apolipoprotein A1 gene (APOA1) contributes to apoA-I and HDL cholesterol levels and risk of IHD in the general population. DESIGN: We resequenced the regulatory and coding regions of APOA1 in 190 individuals from the Copenhagen City Heart Study with the lowest 1% (n=95) and highest 1% (n=95) apoA-I levels. Two single-nucleotide polymorphisms (SNPs) were subsequently genotyped in the Copenhagen City Heart Study (n=10,273) and in 2361 cases with IHD (the Copenhagen Ischemic Heart Disease Study). RESULTS: In total, 13 genetic variants were identified. Three SNPs, g.-560A→C, g.-151C→T, and *181A→G, determined a haplotype that differed between high and low apoA-I groups (6 vs. 1%, P=0.002). Genotype combinations of two SNPs, the g.-560A→C (tagging the g.-560A→C/g.-151C→T/*181A→G haplotype) and g.-310G→A (situated near a potential functional promoter site), were associated with increases in apoA-I and HDL cholesterol levels of up to 6.6 and 8.5%, respectively, resulting in theoretically predicted reductions in risk of 9 and 8% for IHD and 14 and 12% for myocardial infarction (MI). Despite this, these same genotype combinations were not associated with decreased risk of IHD or MI. CONCLUSION: Common genetic variation in APOA1 associated with increased apoA-I and HDL cholesterol levels did not associate with decreased risk of IHD or MI.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The causative role of HDL-C for protection against CVD has been questioned in several studies utilizing Mendelian randomization. 87,89,91,92”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [91]
In the citing paper
“The causative role of HDL-C for protection against CVD has been questioned in several studies utilizing Mendelian randomization.87,89,91,92”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [91]
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423 · cited 3×
“LDL cholesterol levels were calculated with the Friedewald equation if triglycerides were lower than 4 mmol/liter but measured directly at higher triglyceride levels (21).”
MethodInfluentialEffects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139 · cited 1×
“Furthermore, clinical trials have shown that cholesteryl ester transfer protein inhibition that raises HDL cholesterol increases coronary disease (38).”
BackgroundNordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058 · cited 1×
“We suggest that the observed atheroprotective effect of high levels of apoA-I and HDL cholesterol in epidemiological studies may not be due to the apoA-I and HDL elevation itself but may be caused by the concomitant reduction in levels of triglycerides and thus in atherogenic remnant lipoproteins (40).”
BackgroundSelf-citationNewly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585 · cited 1×
“Furthermore, neither candidate gene studies of APOA1 SNPs (15, 18) nor a genome-wide association study (39) has associated APOA1 SNPs with cardiovascular risk.”
BackgroundWalldius, G., Jungner, I., Holme, I., Aastveit, A. H., Kolar, W., & Steiner, E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07098-2 · Cited by 1,229
Multiple Rare Alleles Contribute to Low Plasma Levels of HDL Cholesterol
Cohen, J. C., Kiss, R. S., Pertsemlidis, A., Marcel, Y. L., McPherson, R., & Hobbs, H. H. (2004) · Science · doi:10.1126/science.1099870 · Cited by 1,108 · cited 1×
“This further supports the usefulness of the extreme group strategy for the detection of functionally important variants, as shown previously by us and others (2, 31).”
Clarke, R., Shipley, M., Lewington, S., Youngman, L., Collins, R., Marmot, M., & Peto, R. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010013 · Cited by 877 · cited 1×
“The theoretically predicted hazard ratios as a function of HDL cholesterol levels were corrected for regression dilution bias (24).”
BackgroundGenetically elevated C-reactive protein and ischemic vascular disease
Zacho, J., Tybjærg-Hansen, A., Jensen, J. S., Grande, P., Sillesen, H., & Nordestgaard, B. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707402 · Cited by 839
Self-citationMacrophage Reverse Cholesterol Transport: Key to the Regression of Atherosclerosis?
Cuchel, M., & Rader, D. J. (2006) · Circulation · doi:10.1161/circulationaha.104.475715 · Cited by 527
Frikke-Schmidt, R. (2008) · JAMA · doi:10.1001/jama.299.21.2524 · Cited by 464
Self-citation(1997) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a015259 · Cited by 265 · cited 1×
“IHD was MI or characteristic symptoms of stable angina pectoris (20).”
BackgroundSchnohr, P. (2002) · European Heart Journal · doi:10.1053/euhj.2001.2842 · Cited by 195
The Effects of Altered Apolipoprotein A-I Structure on Plasma HDL Concentration
Sorci-Thomas, M. G., & Thomas, M. J. (2002) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(01)00163-3 · Cited by 189 · cited 1×
“tablished relations to IHD (5, 6), the study of single-nu-”
BackgroundHuman apolipoprotein A-I gene promoter polymorphism: association with hyperalphalipoproteinemia.
Pagani, F., Sidoli, A., Giudici, G. A., Barenghi, L., Vergani, C., & Baralle, F. E. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42608-2 · Cited by 114
Chroni, A., Liu, T., Fitzgerald, M. L., Freeman, M. W., & Zannis, V. I. (2004) · Biochemistry · doi:10.1021/bi035813p · Cited by 99
Johannsen, T. H., Kamstrup, P. R., Andersen, R. V., Jensen, G. B., Sillesen, H., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1342 · Cited by 98 · cited 2×
“For example, the 480C3T promoter variant of the hepatic lipase gene (LIPC) increases levels of HDL cholesterol but either increases (37) or has no effect on risk of IHD (22).”
BackgroundMethodSelf-citationTybjærg‐Hansen, A., Nordestgaard, B. G., Gerdes, L. U., Færgeman, O., & Humphries, S. E. (1993) · Atherosclerosis · doi:10.1016/0021-9150(93)90202-6 · Cited by 89
Self-citationTranscriptional regulatory mechanisms of the human apolipoprotein genes in vitro and in vivo
Zannis, V. I., Kan, H.-Y., Kritis, A., Zanni, E. E., & Kardassis, D. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200104000-00012 · Cited by 88 · cited 1×
“310G3A is located close to regulatory element B (28) and a drug-responsive element (33) in the APOA1 promoter, which could be important sites for APOA1 regulation.”
BackgroundAngotti, E., Mele, E., Costanzo, F., & Avvedimento, E. V. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32445-6 · Cited by 76
Juo, S. H., Wyszynski, D. F., Beaty, T. H., Huang, H., & Wilson, J. E. B. (1999) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19990129)82:3<235::aid-ajmg8>3.0.co;2-h · Cited by 65 · cited 1×
“In agreement with a metaanalysis of earlier studies (n 3413) (32), we showed that g.”
ResultMiccoli, R., Bertolotto, A., Navalesi, R., Odoguardi, L., Boni, A., Wessling, J., Funke, H., Wiebusch, H., von Eckardstein, A., & Assmann, G. (1996) · Circulation · doi:10.1161/01.cir.94.7.1622 · Cited by 59
Wang, X. L., Badenhop, R. F., Humphrey, K. E., & Wilcken, D. E. L. (1996) · Genetic Epidemiology · doi:10.1002/(sici)1098-2272(1996)13:1<1::aid-gepi1>3.0.co;2-d · Cited by 58
Kamboh, M. I., Aston, C. E., Nestlerode, C. S., McAllister, A. E., & Hamman, R. F. (1996) · Atherosclerosis · doi:10.1016/s0021-9150(96)05966-7 · Cited by 58
Polymorphisms at the 5'-end of the apolipoprotein AI gene and severity of coronary artery disease.
Wang, X. L., Liu, S. X., McCredie, R. M., & Wilcken, D. E. L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118802 · Cited by 58
Peacock, R. E., Hamsten, A., Johansson, J., Nilsson‐Ehle, P., & Humphries, S. E. (1994) · Clinical Genetics · doi:10.1111/j.1399-0004.1994.tb04159.x · Cited by 53
The effects of scale: variation in the APOA1/C3/A4/A5 gene cluster
Clark, A. G., Nickerson, D. A., Weiss, K. M., Salomaa, V. V., Boerwinkle, E., Fullerton, S. M., Buchanan, A. V., Sonpar, V. A., Steng�rd, J. H., Smith, J. D., et al. (2004) · Human Genetics · doi:10.1007/s00439-004-1106-x · Cited by 51
Hokanson, J. E., Cheng, S., Snell-Bergeon, J. K., Fijal, B. A., Grow, M. A., Hung, C., Erlich, H. A., Ehrlich, J., Eckel, R. H., & Rewers, M. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1208 · Cited by 51
Apolipoprotein A1 Gene Polymorphisms and Risk of Early Coronary Disease
Reguero, J. R., Cubero, G. I., Batalla, A., Álvarez, V., Hevia, S., Cortina, A., & Coto, E. (1998) · Cardiology · doi:10.1159/000006849 · Cited by 47
Boekholdt, S., Souverein, O., Tanck, M., Hovingh, G., Kuivenhoven, J., Peters, R., Jansen, H., Schiffers, P., Van Der Wall, E., Doevendans, P., et al. (2006) · Clinical Genetics · doi:10.1111/j.1399-0004.2006.00578.x · Cited by 46 · cited 1×
“associated with increased levels of apoA-I or HDL cholesterol (7–10) or with no change (11).”
BackgroundTuteja, R., Tuteja, N. K., Melo, C. A., Casari, G., & Baralle, F. E. (1992) · FEBS Letters · doi:10.1016/0014-5793(92)80597-a · Cited by 45 · cited 1×
“In vitro studies of this variant have shown decreased expression (34), increased expression (35), and no effect on promoter activity (36).”
BackgroundLarson, I., Ordovás, J. M., Barnard, J., Hoffmann, M., Feussner, G., Lamon‐Fava, S., & Schaefer, E. J. (2002) · Clinical Genetics · doi:10.1034/j.1399-0004.2002.610302.x · Cited by 40
Homozygous alpha-thalassemia associated with hypospadias in three survivors
Fung, T. Y., Lau, T. K., Li, C. K., & Li, C. K. (1999) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19990129)82:3<254::aid-ajmg11>3.0.co;2-j · Cited by 40
Shioji, K., Mannami, T., Kokubo, Y., Goto, Y., Nonogi, H., & Iwai, N. (2004) · Journal of Human Genetics · doi:10.1007/s10038-004-0172-1 · Cited by 36
Recalde, D., Velez‐Carrasco, W., Civeira, F., Cenarro, A., Gómez‐Coronado, D., Ordovás, J. M., & Pocoví, M. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00555-4 · Cited by 35
Brown, C. M., Rea, T. J., Hamon, S., Hixson, J. E., Boerwinkle, E., Clark, A. G., & Sing, C. F. (2006) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0037-x · Cited by 32
Association between MspI polymorphism of the APO AI gene and Type 2 diabetes mellitus
Morcillo, S., Cardona, F., Rojo‐Martínez, G., Esteva, I., Ruiz-de-Adana, M. S., Tinahones, F. J., Gómez‐Zumaquero, J. M., & Soriguer, F. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01514.x · Cited by 23 · cited 1×
“Previous studies have shown increased HDL cholesterol levels (8, 12, 13) or no effect of the g.”
BackgroundProtein-DNA Interactions at a Drug-responsive Element of the Human Apolipoprotein A-I Gene
Zhang, X., Chen, Z.-Q., Wang, Z., Mohan, W. S., & Tam, S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.43.27152 · Cited by 21
Danek, G. M., Valenti, M., Baralle, F. E., & Romano, M. (1998) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00029-3 · Cited by 18 · cited 1×
“In vitro studies of this variant have shown decreased expression (34), increased expression (35), and no effect on promoter activity (36).”
BackgroundQuang, H., Nazih, H., Luc, G., Arveiler, D., Ferrières, J., Evans, A., Amouyel, P., Cambien, F., Ducimetière, P., & Bard, J. (2009) · Metabolism · doi:10.1016/j.metabol.2008.09.026 · Cited by 12
Cited by
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
“The causative role of HDL-C for protection against CVD has been questioned in several studies utilizing Mendelian randomization.(87,89,91,92) Recent studies suggest that HDL has a complex role in atherogenesis and that the presence of dysfunctional HDL may be more relevant to the ESC/EAS Guidelines 3016”
BackgroundCommon variants associated with plasma triglycerides and risk for coronary artery disease
Do, R., Willer, C. J., Schmidt, E. M., Sengupta, S., Gao, C., Peloso, G. M., Gustafsson, S., Kanoni, S., Ganna, A., Chen, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2795 · Cited by 862
Mendelian randomization of blood lipids for coronary heart disease
Holmes, M. V., Asselbergs, F. W., Palmer, T. M., Drenos, F., Lanktree, M. B., Nelson, C. P., Dale, C. E., Padmanabhan, S., Finan, C., Swerdlow, D. I., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/eht571 · Cited by 748
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Metadata
- Authors
- Haase, C. L., Tybjærg-Hansen, A., Grande, P., & Frikke-Schmidt, R.
- Affiliations
- University of Copenhagen (DK)
- ORCID
- Haase, Christiane L.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2010-12
- Volume
- 95
- Issue
- 12
- Pages
- E500-E510
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2074535217
- Cited by
- 104
- References
- 39
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 4 · 2022: 8 · 2021: 8 · 2020: 6 · 2019: 6 · 2018: 7 · 2017: 8 · 2016: 9 · 2015: 11 · 2014: 4 · 2013: 10 · 2012: 9
- FWCI
- 4.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- apolipoprotein A-I, HDL cholesterol, ischemic heart disease, myocardial infarction, genetic variants, single nucleotide polymorphisms, haplotypes, genetic association, cardiovascular risk, promoter polymorphism
- MeSH terms
- Aged, Chromosomes, Human, Pair 11, Denmark, DNA, Family, Female, Gene Expression Regulation, Genotype, Humans, Cholesterol, HDL, Male, Middle Aged, Phenotype, Genetic Variation, Apolipoprotein A-I, Myocardial Ischemia, Twin Studies as Topic, Risk Assessment, Polymorphism, Single Nucleotide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.